 This multiple ascending dose MAD study in healthy subjects and subjects with mild to moderate renal impairment will evaluate the safety, tolerability and pharmacokinetics of KBP-5074. Safetytolerability data and Pharmacokinetics PKPharmacodynamics PD plasma aldosterone, serum potassium, UACR and Blood Pressure relationships will be explored to support the selection of dosing regimens of KBP-5074 that are suitable for the Phase IIIII study. 